Large effects on body mass index and insulin resistance of fat mass and obesity associated gene (FTO) variants in patients with polycystic ovary syndrome (PCOS): a case control study

Susanne Tan¹, André Scherag², Onno Eilard Janssen³, Susanne Hahn⁴, Harald Lahner¹, Tiina Dietz¹, Susann Friedel⁵, Harald Grallert⁶, Carla Ivane Ganz Vogel⁵, Rainer Kimmig⁷, Thomas Illig⁶, Klaus Mann¹, Johannes Hebebrand⁵, Anke Hinney⁵§

¹Department of Endocrinology and Division of Laboratory Research, University of Duisburg-Essen, Essen, Germany
²Institute for Medical Informatics, Biometry and Epidemiology, University of Duisburg-Essen, Essen, Germany
³Endokrinologikum Hamburg, Center for Endocrine and Metabolic Diseases, Hamburg, Germany
⁴Center for Endocrine and Metabolic Diseases, Wuppertal, Germany
⁵Department of Child and Adolescent Psychiatry, University of Duisburg-Essen, Essen, Germany
⁶Institute of Epidemiology, GSF - National Research Center for Environment and Health, Munich, Germany
⁷Department of Gynecology and Obstetrics, University of Duisburg-Essen, Essen, Germany

§Corresponding author

Email addresses:

ST: susanne.tan@uk-essen.de
AS: andre.scherag@uk-essen.de
OEJ: onno@onnojanssen.de
SH: mail@susannehahn.com
HL: harald.lahner@uni-due.de
TD: tiina.dietz@uk-essen.de
SF: susann.friedel@uni-duisburg-essen.de
HG: harald.grallert@helmholtz-muenchen.de

CIGV: carla.vogel@uni-due.de
RK: rainer.kimmig@uk-essen.de
TI: illig@helmholtz-muenchen.de
KM: klaus.mann@uk-essen.de
JH: johannes.hebebran@uk-essen.de
AH: anke.hinney@uni-due.de
Abstract

Background

The polycystic ovary syndrome (PCOS), a common endocrine disorder in women of fertile age mainly characterised by chronic anovulation and hyperandrogenism, is often associated with insulin resistance (IR) and obesity. Its etiology and the role of IR and obesity in PCOS are not fully understood. We examined the influence of validated genetic variants conferring susceptibility to obesity and/or type 2 diabetes mellitus (T2DM) on metabolic and PCOS-specific traits in patients with PCOS.

Methods

We conducted an association study in 386 patients with PCOS (defined by the Rotterdam-criteria) using single nucleotide polymorphisms (SNPs) in or in proximity to the fat mass and obesity associated gene (FTO), insulin-induced gene-2 (INSIG2; rs7566605), transcription factor 7-like 2 gene (TCF7L2) and melanocortin 4 receptor gene (MC4R).

Results

The FTO-risk allele was associated with IR traits and measures of increased body weight. In addition, the TCF7L2 SNP was associated with body weight traits. For the SNPs in the vicinity of INSIG2 and MC4R and for the other examined phenotypes there was no evidence for association. In PCOS the observed per risk allele effect of FTO intron 1 SNP rs9939609 on BMI was +1.56 kg/m$^2$ whereas it was +0.46 kg/m$^2$ in ~2,000 unselected de novo genotyped females (KORA-S4), which is consistent across multiple reports.

Conclusion

The stronger effect on body weight of the FTO SNP in PCOS might well have implications for the etiology of the disease.
The polycystic ovary syndrome (PCOS) is a common endocrinopathy affecting about 6% of women in fertile age [1]. It is classically characterised by chronic anovulation, hyperandrogenism and polycystic ovarian morphology on ultrasonography [2]. In addition, PCOS is often accompanied by obesity and impaired glucose tolerance, as a close relationship exists between PCOS and insulin resistance (IR) [3]. Despite a growing body of evidence demonstrating a substantial heritability of PCOS and the intrinsic impact of IR on the development of PCOS, its etiology and underlying pathophysiology still remain elusive.

To date, multiple genetic studies in PCOS have been performed examining genes coding for enzymes of steroid biosynthesis like CYP11, CYP17, CYP19, androgen receptor, insulin, insulin receptor and enzymes in the post-receptor signal cascade of insulin without detection of a variant contributing substantially to the development of the PCOS phenotype [4-7].

Genome-wide association studies (GWAS) offer a new approach to gene discovery unbiased with regard to presumed functions or locations of causal variants using up to one million single nucleotide polymorphism (SNP) distributed evenly across the whole genome. In the field of human body weight regulation these studies already have a major impact on the identification of relevant polygenes.

For instance, common variants in the fat mass and obesity associated gene (FTO) predispose to an elevated body mass index (BMI) with an increase of 0.36 kg/m² BMI units per risk allele. Homozygous risk allele carriers weighed about three kilograms more and had 1.67-fold higher odds for obesity compared to adults not inheriting the risk allele [8]. This robust association was even detectable in the first GWAS for early onset extreme obesity [9]. With regard to insulin sensitivity, a recent British study in healthy adults indicated an association between polymorphisms of the FTO gene and a decrease in insulin sensitivity which was presumably BMI mediated [10]. Barber et al. additionally demonstrated an association between PCOS status and FTO SNPs in a case-control study [11]. Using a similar approach, Attaoua et al. discussed the potential role of FTO variants for the glucose intolerance component of metabolic syndrome in patients with PCOS [12].
Association with increased risk of obesity has also been demonstrated for the SNP rs7566605 located ~10kb upstream of the *insulin-induced gene-2* (*INSIG2*), which was detected in the first population-based GWA for obesity [13]. Results concerning the influence of this SNP on obesity risk are conflicting, as not all studies detected the association with obesity [14] [15] [16] [17]. However, in a meta-analysis of case-control and family-based approaches comprising about 17,000 individuals a marginal effect of rs7566605 on obesity was still present [18]. Recently, Reinehr et al. showed a lower success rate in a lifestyle intervention for obese CC-homozygous children [19].

A validated gene for type two diabetes mellitus (T2DM) is the *transcription factor 7-like 2* gene (*TCF7L2*). Identified via a conventional genome wide scan for T2DM and subsequent fine mapping [20] it has been convincingly confirmed in numerous studies including GWAS [21-23]. The gene codes for a stimulating regulator of proglucagon gene expression [24]. The proglucagon gene is post-translationally processed to produce GLP-1, a stimulator of insulin secretion and biosynthesis and an inhibitor of glucagon release [25]. GWAS reported association of a SNP in *TCF7L2* with T2DM and IR in Caucasians [20, 26, 27] but a negative association to body weight [20, 27-29]. In PCOS patients, using a sample size and design similar to their *FTO* study [11], a case-control comparison did not provide evidence for an association of *TCF7L2* variants with disease status [30].

While the aforementioned genes were mostly detected by genome-wide association approaches, a further (negative) correlation to weight status was robustly found for a non-synonymous polymorphism Val103Ile in the *melanocortin-4 receptor* gene (*MC4R*) [31-33]. Interestingly, the genetic locus in the vicinity of the *MC4R* was recently also detected in a large-scaled GWA [34]. The respective SNP which is associated with obesity was detected 188 downstream (3’end) of the *MC4R*; its effect is presumably exerted by an influence on the expression of the gene. Additionally, another SNP near the previously described one, was shown to be associated with waist circumference and insulin resistance [35].

Given the high prevalence of obesity in PCOS and the compelling evidence for a substantial genetic background of both PCOS and obesity, known obesity susceptibility genes emerge as eligible candidates that might also be involved in the development of PCOS. Therefore we examined the influence of the described genetic variants on obesity and other endophenotypes in patients with
PCOS. We considered polymorphisms in or near \textit{FTO}, \textit{INSIG2}, \textit{TCF7L2} and \textit{MC4R} that are all well supported by large data collections of GWAS or meta-analyses for our analyses.

\section*{Methods}

\subsection*{Patient Recruitment}
Consecutive, currently untreated PCOS patients ($n=386$) were recruited between 2/2001 and 1/2007 at the outpatient clinic of the Department of Endocrinology and Division of Laboratory Research, University of Duisburg-Essen, Germany. Some patients were also attracted by the PCOS homepage of the clinic (www.pco-syndrom.de). PCOS was defined according to the 2003 Rotterdam criteria, so diagnosis of PCOS was established, if two of the three criteria chronic anovulation, clinical and/or biochemical hyperandrogenism and polycystic ovaries (PCO) were fulfilled and other pituitary, adrenal or ovarian diseases could be excluded [2]. The study protocol was approved by the Ethics Committee of the University of Essen. All subjects gave written informed consent before entering the study.

\subsection*{Clinical Characterization of Patients}
Participants were carefully characterized with regard to medical history, clinical and sociodemographic variables using questionnaires, interview, and physical examinations, as previously described in detail [36]. Free androgen index (FAI) was calculated as total testosterone [nmol/l] x 100/SHBG [nmol/l]. Bioavailable testosterone concentration was calculated based on measured testosterone, SHBG and albumine levels [37]. Variables of IR and β-cell function were evaluated using a 3-h oral glucose tolerance test. After an overnight fast of 12 h patients ingested 75 g glucose and had their glucose and insulin levels determined at baseline and at 30, 60, 90, 120 and 180 min. IR was defined by the homeostasis model assessment (HOMA) model [38] and hyperinsulinemia by calculating the area under the curve of insulin response (AUCI).

\subsection*{Females from the population-based sample (KORA-S4)}
KORA (Kooperative Gesundheitsforschung im Raum Augsburg, Survey 4; ‘Cooperative Health Research in the Region of Augsburg’) is an epidemiological study group including 4,261 German adults representative of the population within the age range of 25-74 years in the city and region of Augsburg (Bavaria, Germany); probands were recruited between 1999-2001 [39]. FTO (rs9939609) genotypes as well as phenotype data were available for 1,971 females (mean BMI 26.96 ± 5.28 kg/m², mean age 48.85 ± 13.69 years).

**Biochemical Analyses**

Automated chemiluminescence immunoassay systems were used for the determination of LH, FSH, TSH, testosterone, estradiol, cortisol, free thyroxine, prolactin, blood glucose (ADVIA Centaur, Siemens, Germany), ACTH, dehydroepiandrosterone sulfate, androstenedione, sex hormone-binding globulin, insulin and insulin-like growth factor (IMMULITE 2000, Siemens, Germany). Measurement of blood glucose was performed by photometric determination (ADVIA 2400, Siemens, Germany). Intraassay variation was < 5% and interassay variation was < 8% for all measured variables. 17-hydroxyprogesterone was measured by the BIOSOURCE 17-alpha-OH-RIA-CT kit (Biosource International, California, USA) (analytical sensitivity 0.02 ng/ml) provided by IBL Hamburg (IBL, Gesellschaft für Immunchemie und Immunbiologie, Hamburg, Germany). The intra- and interassay coefficients of variation were 5.6 and 7.2% respectively.

Except for amenorrhoic women, all laboratory variables were determined in the early follicular phase of the menstrual cycle.

**Genotyping**

Genomic DNA was isolated from EDTA-anticoagulated blood using standard procedures. Genotyping of FTO SNP rs9939609 was performed by matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) analysis of allele-dependent primer extension products as described elsewhere [40]. For MC4R Val103Ile (rs2229616), DNA samples were genotyped as described previously.

MC4R SNPs rs17782313 and rs12970134 were genotyped using TaqMan® assays (Applied Biosystems, Foster City, CA, USA). All TaqMan® probes and primers were
purchased from Applied Biosystems (assays on demand; www.appliedbiosystems.com). For the TCF7L2 rs79031746, genotyping was performed by allele-specific PCR reactions (tetra-ARMS PCR; primers were as follows: (forward inner primer (C allele):
5'-TAGAGAGCTAAGCCTTTTCTAGAGAC-3'; reverse inner primer (T allele): 5'-CTCATACGGCAATTAAATTATAGAA-3'; forward outer primer: 5'-AATTTTTCCATGTGAAGACATAC-3'; reverse outer primer: 5'-AAGAGATGAAATGTCAGCTGAAG-3'). The C allele is detected by a 202bp amplicon and the T allele by a 272bp amplicon. The product size of two outer primers is 424bp.

Genotyping of INSIG2 SNP rs7566605 was carried out by PCR-RFLP with Bsp143I (digests the C-allele; primers: 5'-TGAAGTTGATCTAATGTTCTCTCC-3' and 5'-AAACCAAGGAATCGAGAGC-3').

PCR products were run on ethidium bromide-stained 2.5% agarose gels. Positive controls for the variant alleles and a negative control (water) were run on each gel. To validate the genotypes, allele determinations were rated independently by at least two experienced individuals. Discrepancies were resolved unambiguously either by reaching consensus or by retyping. Missings were retyped twice.

**Statistical Analyses**

All genotype distributions were tested for deviations from Hardy Weinberg equilibrium (HWE) using the PLINK software (Version 1.04 1 [41]) and no evidence for such deviations was detected (all p>>0.4). All endophenotypes were analysed by either linear or logistic regression analyses using age in years as a covariate. Except for MC4R (rs2229616), where a dominant mode of inheritance was assumed, each SNP was analyzed under an (log-) additive genetic model. Nominal two-sided p-values, genetic effect sizes estimates and 95% confidence intervals (CI) for the estimates were derived. To address, to some extent, the problem of testing multiple hypotheses, we also compared our strongest association signals (see Table 3) to \( \alpha = 0.0025 \) which is Bonferroni-adjusted for 20 independent tests (5 gene loci counting MC4R twice and 4 phenotype groups (metabolic / obesity related variables, variables of IR, PCOS symptoms, variables of hyperandrogenemia)).
As secondary analyses, robust linear regressions were used for the comparison of the PCOS patients with the population-based females and for an exploration of joint or interaction effects of *FTO* and *TCF7L2* SNPs; model assumptions were checked graphically.

Power calculations were done with the software QUANTO (Version 1.2.3, http://hydra.usc.edu/gxe). 386 PCOS patients were estimated to yield a power > 0.80 to detect a standardized additive genetic effect size of 0.5 ($\alpha = 0.05$; two-sided) assuming a minor allele frequency (MAF) of 5% and a standard normally distributed phenotype. For larger MAFs like 46.2%, smaller effect sizes of 0.2 will be detectable with a similar power. Thus, except for rs2229616 with its low allele frequency (1.6%, Table 1), the study was well powered to detect moderate genetic effects.

**Results**

The clinical and phenotypical characteristics of the investigated patients with PCOS as well as the estimated MAFs are given in Table 1.

Exploration of associations between genotypes and metabolic/obesity related variables in patients with PCOS revealed some evidence for an association of variants in *FTO* and *TCF7L2*, whereas no indication of association was observable for SNPs in *INSG2* and *MC4R* (see Table 2).

We estimated that each risk allele of the polymorphism rs9939609 of *FTO* increased the body weight by ~4.6 kg, whereas the BMI was increased by ~1.6 kg/m$^2$ and the waist circumference increased by ~3.5 cm. Of note, the effect size of rs9939609 on BMI in PCOS was larger than in unselected females from the general population (see Figure 1). For the *TCF7L2* polymorphism rs7903146 the per risk allele effect was ~4.2 kg body weight, ~1.4 kg/m$^2$ BMI and ~3.4 cm waist circumference, respectively (for details see Table 2). Furthermore, there was no evidence for a potentially strong interaction or a correlation between the *FTO* (adjusted effect 1.35 kg/m$^2$ in robust linear regression) and the *TCF7L2* locus (adjusted effect 1.45 kg/m$^2$).

Moreover, *FTO* variant rs9939609 was associated with variables of insulin resistance (see Table 3). As an example, the estimated per risk allele effect was 3.25 mU/l for fasting insulin, which changed to
1.88 mU/l (95% CI 0.22 mU/l; 3.54 mU/l, p-value = 0.03) if BMI was added as a covariate to the regression model. Thus, even after correcting for BMI, a genetic effect of rs9939609 on fasting insulin levels was observed.

By contrast, there was no evidence for an association of SNPs in INSIG2, TCF7L2 and MC4R with variables of insulin resistance (for details see Table 3).

Finally, we investigated the relationship between the variants and PCOS specific characteristics (for details see Tables 4 and 5). There was no association to chronic anovulation, hirsutism, acne, alopecia or androgen levels for any of the variants. Interestingly, we observed that the obesity risk allele A of the FTO variant rs9939609 was less frequently observed in patients with polycystic ovarian morphology (PCO) compared to PCOS patients without PCO (OR = 0.57, 95% CI 0.36;0.88, p-value = 0.01) and even after correcting for BMI this relationship was still present (OR = 0.60, 95% CI 0.37;0.93, p-value = 0.02).

**Discussion**

The influence of FTO intron1 variation on body weight related phenotypes in patients with PCOS is underscored. In population-based GWAS the estimated per risk allele effect ranged between 0.36 kg/m² [8] and 0.66 kg/m² [42] for statistical models with a slightly different set of covariates. In our PCOS sample, we estimated an average effect of the FTO risk allele of 1.56 kg/m² (95% CI 0.34 kg/m²; 2.78 kg/m²) including age as a quantitative covariate. Moreover, the impact of the FTO variants on BMI is larger in PCOS patients than in the general population with an average effect of the FTO risk allele of 0.46 kg/m² (95% CI 0.17 kg/m²; 0.75 kg/m²) as shown in Figure 1. Of note, our finding is surprisingly similar to that of Barber et al. [11] who reported a per risk allele effect of 1.1 kg/m² (95% CI -0.9 kg/m²; 3.2 kg/m²) in their PCOS cases and only 0.5 kg/m² (95% CI -0.1 kg/m²; 1.3 kg/m²) in their controls.

Moreover, this study is, to our knowledge, the first to describe a correlation between FTO rs9939609 and insulin resistance, resp. hyperinsulinemia reflected in higher fasting insulin and HOMA-IR resp. AUCI levels, in patients with PCOS. Even after statistically correcting for BMI, this effect, though
weaker, was still present. Other study groups could not demonstrate an association between FTO and IR in obese resp. T2DM patients [43, 44]. In PCOS, FTO variation seems to be a key marker for IR, either directly i.e. to some degree independent of BMI/obesity or secondary due to its impact on body weight which in turn has an impact on glucose intolerance and diabetes. Barber et al. at first demonstrated an association between FTO and PCOS status and hypothesized a mediation of this association by adiposity. However, in this British sample, no IR data were available. In a French sample FTO was associated with both glucose intolerance and metabolic syndrome [12] without finding an association to IR.

The greater effect on BMI and association to IR in PCOS possibly reflects a pathogenetic function of the FTO gene in the development of PCOS. This study and the data from Barber et al. demonstrated, that the FTO gene does not influence any of the PCOS defining traits neither directly nor indirectly via an effect on obesity or IR. In this German cohort, it is even less frequently associated with PCO. In case of a pathogenetic role of FTO in PCOS, it seems to be limited to determine only the metabolic phenotype.

As second strongest signal, we found association between the T2DM susceptibility gene TCF7L2 risk allele and obesity related traits in patients with PCOS. The TCF7L2 obesity association was stochastically independent of the FTO association if assessed in a multiple regression analysis. While some have reported analogous associations of TCF7L2 and obesity related traits [45] others did not find an influence on body weight [28, 29, 46-49]. As we observed no evidence for an association of TCF7L2 with IR or other PCOS specific symptoms, common variants of TCF7L2 most likely influence T2DM susceptibility through impairment of insulin secretion rather than IR [49, 50]. Interestingly, this observation is consistent with the PCOS data of Barber et al. [11] who failed to detect association of TCF7L2 variation but who do not report on the genotype dependent BMI-distribution.

Finally, our data on rs7566605 located ~10kb upstream of INSIG2 and on markers in proximity to MC4R provided no evidence for an involvement in the development of PCOS or related endophenotypes.

**Conclusion**
In summary, we explored (mainly) GWA-derived candidate gene markers in patients with PCOS and found that the impact of \textit{INSIG2}, \textit{TCF7L2} and \textit{MC4R} SNPs might either be rather weak or not present at all. In case of \textit{TCF7L2} further studies on body weight related phenotypes are warranted. As a main finding, however, our data strongly support the idea that intron1 \textit{FTO} variation is predominantly associated with the metabolic aspects of PCOS with some emphasis on IR. Interestingly, the estimated effect on obesity seems to be larger than the effect derived from population-based samples. The stronger effect on body weight of the \textit{FTO} SNP in PCOS might well have implications for the etiology of the disease. Functional studies in tissues of PCOS patients are urgently needed to dissolve the relationship between those factors.

**Competing Interests**

The authors declare that they have no competing interests.

**Authors’ contributions**

ST contributed substantially to conception and design of the study, acquisition of data, analysis and interpretation of data and drafted the manuscript.

AS contributed substantially to conception and design of the study, analysis of data, performed the statistical analysis and drafted the manuscript.

OEJ, SH, HL, TD, RK and KM contributed to acquisition of data and revised the manuscript critically for important intellectual content.

SF and CIGV carried out the molecular genetic studies for polymorphisms of \textit{TCF7L2}, \textit{INSIG2} and \textit{MC4R} and revised the manuscript critically for important intellectual content.

HG and TI contributed to acquisition of data, carried out the molecular genetic studies for polymorphisms of \textit{FTO} and revised the manuscript critically for important intellectual content.
JH and AH contributed substantially to conception and design of the study, analysis and interpretation of data and were involved in drafting the manuscript and have given final approval of the version to be published.

All authors read and approved the final manuscript.

Acknowledgments

We thank the probands for their participation.

This work was supported by grants from the Bundesministerium fuer Bildung und Forschung (NGFNPLUS), the Deutsche Forschungsgemeinschaft (HE 1446/4-1) and the European Union (FP6 LSHMCT-2003-503041).

References


41. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J, Sklar P, de Bakker PI, Daly MJ, Sham PC: PLINK: a tool set for whole-genome association and population-based linkage analyses. *Am J Hum Genet* 2007, 81:559-575.


**Figures**

Figure 1 - Relationship between the FTO SNP rs9939609, BMI and age in females for the general population and in patients with PCOS.

Each dot represents one observation; the lines are derived from a robust linear regression on the complete data set of females with BMI as outcome and age (linear), group, genotype in the log-additive model and the interaction group x genotype as predictors.

**Tables**

Table 1 – Characteristics of the investigated samples of the patients with PCOS (means and standard deviations or percent).

BMI = Body Mass Index; F/G = hirsutism-Score by Ferriman/ Gallwey; FAI = Free Androgen Index; HOMA-IR = Homeostasis Model Assessment for Insulin Resistance; AUCI = area under the curve of insulin response; MAF = minor allele frequency

Table 2 – Association analysis for the relationship between validated SNPs in the explored candidate genes and quantitative metabolic/obesity related variables in PCOS with genetic effect sizes estimates derived for an additive genetic (*MC4R* rs2229616 dominant genetic model) for the minor allele (see also Table 1).

SNP = Single Nucleotide Polymorphism; BMI = Body Mass Index
Table 3 – Association analysis for the relationship between validated SNPs in the explored candidate genes and quantitative variables of insulin resistance in PCOS with genetic effect sizes estimates derived for an additive genetic model (MC4R rs2229616 dominant genetic model) for the minor allele (see also Table 1).

SNP = single nucleotide polymorphism; HOMA-IR = Homeostasis Model Assessment for Insulin Resistance; AUCI = area under the curve of insulin response

*both associations would have been "significant" at the alpha=0.05 level if correction for 20 statistical tests would have been applied

Table 4 – Association analysis for the relationship between validated SNPs in the explored candidate genes and PCOS symptoms (present/absent) with genetic effect sizes estimates derived for an log-additive genetic model (MC4R rs2229616 dominant genetic model) for the minor allele (see also Table 1). Note that the hirsutism-score was also evaluated quantitatively similar to the other quantitative measures (in italics).

SNP = single nucleotide polymorphism; F/G= hirsutism-score by Ferriman/ Gallwey

Table 5 – Association analysis for the relationship between validated SNPs in the explored candidate genes and quantitative variables of hyperandrogenemia in PCOS with genetic effect sizes estimates derived for a log-additive genetic model (MC4R rs2229616 dominant genetic model) for the minor allele (see also Table 1).

SNP = single nucleotide polymorphism; FAI = Free Androgen Index
Figure 1

Population-based KORA females vs. PCOS patients. BMI (kg/m^2) vs. age (years) for rs9939609 genotype (TT, AT, AA).
Additional files provided with this submission:

Additional file 1: pcos-fto_table1.doc.doc, 33K
http://www.biomedcentral.com/imedia/1423025022281595/supp1.doc

Additional file 2: pcos-fto_table2.doc.doc, 42K
http://www.biomedcentral.com/imedia/2943253872815954/supp2.doc

Additional file 3: pcos-fto_table3.doc.doc, 45K
http://www.biomedcentral.com/imedia/1640692721281595/supp3.doc

Additional file 4: pcos-fto_table4.doc.doc, 55K
http://www.biomedcentral.com/imedia/6912736652815954/supp4.doc

Additional file 5: pcos-fto_table5.doc.doc, 43K
http://www.biomedcentral.com/imedia/1811753975281595/supp5.doc